Differences

This shows you the differences between two versions of the page.

--- triaging_pdl1_3d_requests [2026/04/07 20:18] – gilbert
+++ triaging_pdl1_3d_requests [2026/04/07 20:40] (current) – removed gilbert
@@ Line 1: / Line 1: @@
-====== Gastrointestinal Biomarkers ======
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | Gastric, GEJ, esophageal adenocarcinoma; ESCC | Pembrolizumab, Nivolumab | PDL1 Dako 22C3 %%PharmDX%% | ''PDL1UPPERGIMARCH2026'' |
-| **Claudin 18.2** | Gastric or GEJ adenocarcinoma | Zolbetuximab | VENTANA CLDN18 (43-14A) %%RxDx%% | ''BMCLAUDIN18'' |
-</WRAP>
-====== Head & Neck Biomarkers ======
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | **Advanced** Head and neck squamous cell carcinoma (HNSCC) | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | ''PDL1HNSCC22C3PEMBRO'' |
-| **PD-L1** | **Resectable** Head and neck squamous cell carcinoma (HNSCC) | Pembrolizumab as **Neoadjuvant** | PDL1 Dako 22C3 %%PharmDX%% | ''PDL1HNSCCNEOADPEMBRO'' |
-</WRAP>
-====== Gyne Biomarkers ======
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | Cervical cancer (SCC and Adenocarcinoma) | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | ''PDL1CERVIX'' |
-| **CEP17 SISH** | Ploidy Analysis | N/A | VENTANA Inform Chromosome 17 probe | ''MOLARCEP17'' |
-</WRAP>
-====== Lung Biomarkers ======
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | NSCLC stage IIIb to IV | Pembrolizumab | PDL1 22C3 | ''PDL1NSCLCPEMBRO22C3'' |
-| **PD-L1** | NSCLC stage II to IIIA | Atezolizumab as **Adjuvant** | PDL1 SP263 | ''PDL1NSCLCATEZOSP263'' |
-</WRAP>
-====== Breast Biomarkers ======
-<WRAP div width-100%>
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^
-| **PD-L1** | Triple Negative Breast Cancer (TNBC) | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | ''PDL1TNBC22C3PEMBRO'' |
-</WRAP>